Cargando…
Metformin ameliorates arsenic trioxide hepatotoxicity via inhibiting mitochondrial complex I
Arsenic trioxide (ATO) is a well-accepted chemotherapy agent in managing promyelocytic leukemia. ATO often causes severe health hazards such as hepatotoxicity, dermatosis, neurotoxicity, nephrotoxicity and cardiotoxicity. The production of reactive oxygen species, (ROS) play a significant role in AT...
Autores principales: | Ling, Sunbin, Shan, Qiaonan, Liu, Peng, Feng, Tingting, Zhang, Xuanyu, Xiang, Penghui, Chen, Kangchen, Xie, Haiyang, Song, Penghong, Zhou, Lin, Liu, Jimin, Zheng, Shusen, Xu, Xiao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5775401/ https://www.ncbi.nlm.nih.gov/pubmed/29095437 http://dx.doi.org/10.1038/cddis.2017.482 |
Ejemplares similares
-
Metformin potentiates the effect of arsenic trioxide suppressing intrahepatic cholangiocarcinoma: roles of p38 MAPK, ERK3, and mTORC1
por: Ling, Sunbin, et al.
Publicado: (2017) -
USP22 mediates the multidrug resistance of hepatocellular carcinoma via the SIRT1/AKT/MRP1 signaling pathway
por: Ling, Sunbin, et al.
Publicado: (2017) -
Protective Effects of Eugenol against Hepatotoxicity Induced by Arsenic Trioxide: An Antileukemic Drug
por: Binu, Prakash, et al.
Publicado: (2018) -
Metformin ameliorates methotrexate-induced hepatotoxicity
por: Hadi, Najah R., et al.
Publicado: (2012) -
Ameliorative effects and mechanism of crocetin in arsenic trioxide-induced cardiotoxicity in rats
por: Zhao, Zhifeng, et al.
Publicado: (2020)